Teva’s transformation gains momentum as innovative drug sales rise 33%...

Teva Pharmaceutical Industries reported that its three leading proprietary medicines generated approximately $1.1 billion in quarterly revenue.

The 33 percent rise in innovative drug sales prompted the company to raise its full-year forecasts, helping offset increased U.S. generics competition.